MedTrace Logo

Exhaled Nitric Oxide in Asthma Management

NCT02140684 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2014-05-16

No results posted yet for this study

Summary

This study will compare the absolute and relative effectiveness of managing real-life asthma with and without the use of NIOX MINO® and NIOX Flex® to measure exhaled nitric oxide (eNO) as a marker of underlying airway inflammation to guide appropriate management. As exhaled nitric oxide responds rapidly to environmental changes and can act as a marker of underlying inflammation it is proposed that incorporating eNO monitoring into routine asthma management treatment allows strategies to be more accurately tailored to the patients needs, increasing the probability of good asthma control.

Conditions

Interventions

DEVICE

eNO monitoring

Patient undergoing review with eNO monitored using either NIOX MINO® and NIOX Flex®

Sponsors & Collaborators

  • Aerocrine AB

    collaborator INDUSTRY

  • Research in Real-Life Ltd

    lead NETWORK

Eligibility

Min Age
6 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02140684 on ClinicalTrials.gov